Dapagliflozin protects heart function against type-4 cardiorenal syndrome through activation of PKM2/PP1/FUNDC1-dependent mitophagy.

Shen, Yang; Peng, Xiaojie; Ji, Haizhe; Gong, Wei; Zhu, Hang; Wang, Jin.

Afiliação

Shen Y; Department of Cardiology, School of Medicine, South China University of Technology, Guangzhou, 510006; Department of Cardiology, The Sixth Medical Center of People's Liberation Army General Hospital, Beijing, China.
Peng X; Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China; Department of Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou c
Ji H; Faculty of medicine, Dalian university of technology, Dalian, China.
Gong W; Department of Gastroenterology, Shenzhen Hospital, Southern Medical University, Shenzhen, Guangdong, China; The Third School of Clinical Medicine, Southern Medical University, Shenzhen, Guangdong, China. Electronic address: gongwei@smu.edu.cn.
Zhu H; Department of Cardiology, School of Medicine, South China University of Technology, Guangzhou, 510006; Department of Cardiology, The Sixth Medical Center of People's Liberation Army General Hospital, Beijing, China. Electronic address: zhuhang301@outlook.com.
Wang J; Department of Vascular Medicine, Peking University Shougang Hospital, Beijing 100144, China. Electronic address: nkuwangjin@163.com.

Int J Biol Macromol ; 250: 126116, 2023 Oct 01.

Article em En | MEDLINE | ID: mdl-37541471